TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients
Recently, investigators described in a scientific publications in a recognized international journal (International Journal of Molecular Sciences), the future possibility of the use of an genetic…
Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review
Uromonitor test was recognized and considered by the scientific community as an excellent alternative for the non-invasive follow-up of patients previously diagnosed with Non-Muscle Invasive Bladder…
Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study
The Uromonitor test was recently validated by the scientific community in a international recognized peer-reviewed journal (Frontiers in Genetics) in a multicentric study comprising more than 300…
Uromonitor como una nueva prueba de orina sensible y específica para controlar la recurrencia de pacientes con cáncer vesical muscular no-invasivo
Artículo en URO HOY. Por favor lea el artículo completo aquí.
Premio Emprendedores de la fundación everis
El presidente de la Fundación Everis, Eugenio Galdón, ha otorgado el Premio Everis 2015 a Hugo Prazeres por su proyecto Uromonitor: un examen no invasivo para detectar el cáncer de vejiga mediante el…